TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7720349
Drug: Five small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five small hourly meals
Study: 7188111
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg X 3/day/4 weeks p.o.)
Study: 31472669
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 60 mg.kg-1
Study: 22305829
Drug: TAXUS Liberté
Normalized name: Taxus baccata fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAXUS Liberté stent with concomitant prasugrel therapy (1 year)
Study: 22305829
Drug: Prasugrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel plus aspirin (1 year)
Study: 22305829
Drug: Prasugrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (5 and 10 mg daily doses)
Study: 22305829
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (12 versus 30 months)
Study: 21163755
Drug: DD-I (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD-I (patients before treatment)
Study: 21163755
Drug: DD-II (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD-II (patients after 8 weeks of pharmacological treatment)
Study: 16319260
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron polymaltose complex (300 mg elemental iron per day)
Study: 12411535
Drug: Antioxidants (AOX)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (AOX) ascorbic acid (2 g, I.V.) and alpha‐tocopherol (200 mg, P.O.)
Study: 10445218
Drug: Iron plus
Normalized name: Nu-Iron Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron plus zinc supplementation (12 mg/day of Fe+++ and 12.5 mg/day of Zn++)
Study: 10445218
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12.5 mg/day of Zn++)
Study: 8575690
Drug: Vagifem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagifem (25 micrograms oestradiol) administered as vaginal pessaries daily, 3 weeks prior to surgery
Study: 8575690
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as vaginal pessaries daily, 3 weeks prior to surgery
Study: 8575690
Drug: Preoperative oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative oestradiol treatment
Study: 8575690
Drug: Preoperative placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative placebo treatment
Study: 2427144
Drug: Terfenadine (H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (H1-receptor antagonist)
Study: 24865945
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure (AA) treatment for 8 weeks
Study: 19358184
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (intravenous for 24 hours, followed by oral for 10 days)
Study: 12088166
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment
Study: 12088166
Drug: Acute and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute and maintenance treatment
Study: 8187941
Drug: azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Study: 8187941
Drug: cetirizine tablets
Normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cetirizine tablets 10 mg once daily
Study: 8187941
Drug: azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: azelastine nasal spray
Study: 27849166
Drug: FR104 (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR104 (0.02 mg/kg to 1.500 mg/kg)
Study: 22726372
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels <500 μg/l
Study: 21098580
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote device monitoring (electrocardiogram, blood pressure, body weight) coupled with medical telephone support
Study: 21098580
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote device monitoring
Study: 16351673
Drug: Single steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single steroid injection (methylprednisolone acetate) plus saline injection at 8 weeks
Study: 16351673
Drug: Double steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double steroid injections (methylprednisolone acetate) at baseline and at 8 weeks
Study: 16351673
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single and double injections)
Study: 7034861
Drug: Autogenous wart
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous wart vaccine
Study: 28356068
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (deflated cuff)
Study: 17437877
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (treatment solution with subsequent NaOCl application)
Study: 17437877
Drug: Single treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatments
Study: 17437877
Drug: Treatment time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment time of 5 minutes
Study: 11506819
Drug: Quercetin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (30 mg per day)
Study: 2538094
Drug: Bupivacaine dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine dosage during first stage of labor
Study: 21995590
Drug: NOMAC/E2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen
Study: 21995590
Drug: DRSP/EE (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRSP/EE (3 mg/30 μg) in a 21/7-day regimen
Study: 25066875
Drug: Prostate capsule
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate capsule sparing cystectomy
Study: 21980799
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a high-dose 6-grass pollen preparation
Study: 17924020
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n=210, 354 teeth)
Study: 10702458
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (100 microg. kg(‐1). min(‐1))
Study: 8922197
Drug: Sequential biochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential biochemotherapy (CVD followed by IL-2 and IFN-alpha)
Study: 2861876
Drug: Sulphasalazine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine 1.5 g/day
Study: 2861876
Drug: Sulphasalazine 3
Normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine 3 g/day
Study: 2861876
Drug: Sulphasalazine >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine > 40 mg/kg/day
Study: 30292919
Drug: Skin tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin tests (prick and intradermal tests) for taxanes
Study: 26009799
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT; 100 μg) introduced in a single dose after three hours from the beginning of TK analgesia (TKF treatment)
Study: 26009799
Drug: Ketorolac (0.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (0.86 mg/kg/day) and tramadol (7.2 mg/kg/day) (TK treatment)
Study: 26009799
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT; 100 μg)
Study: 22672794
Drug: I-ONE therapy
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-ONE therapy (PEMFs) for 4 hours/day for 60 days
Study: 22672794
Drug: I-ONE therapy
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-ONE therapy (PEMFs)
Study: 15013307
Drug: MM-Cept 500
Normalized name: IV PREP KIT (CEPTI-SEAL) #26-48-53
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-Cept 500 mg tablets
Study: 15013307
Drug: Cellcept 500
Normalized name: Cellcept 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellcept 500 mg tablets
Study: 1873002
Drug: 12 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/day SF
Study: 1873002
Drug: 24 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g/day SF
Study: 1873002
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day SF
Study: 1873002
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three SF doses
Study: 1873002
Drug: Seaweed preparation
Normalized name: seaweed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaweed preparation
Study: 6126067
Drug: Estazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (1 + 1 + 4 mg)
Study: 31897941
Drug: Cerebrolysin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (50 ml per day for 10 days, followed by two additional treatment cycles with 10 ml per day for 10 days)
Study: 31223399
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (placebo)
Study: 29551172
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (50 mg capsules, three times daily for 14 days)
Study: 29551172
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (three times daily for 14 days)
Study: 26669919
Drug: Ixekizumab 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 160 mg administered at weeks 16, 18, and 20, then every 4 weeks through Week 64
Study: 23778432
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell transfusion (when initial hemoglobin > 10 g/dL)
Study: 11016286
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (50 mW, 830 nm, 10 minutes per session)
Study: 31571834
Drug: Test FDC
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Study: 31571834
Drug: Reference FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Study: 30376823
Drug: Weekly cell
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cell phone counselling and daily text messages
Study: 25271822
Drug: Dexamphetamine sulfate
Normalized name: Dexamphetamine sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine sulfate (0.3 mg/kg) administered intravenously
Study: 17968992
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg/day in 3 divided doses for 3 days)
Study: 16221106
Drug: Losartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan plus conventional therapy (CT)
Study: 16221106
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) alone
Study: 12602521
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral L-ornithine-L-aspartate (OA)
Study: 12602521
Drug: Oral L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-ornithine-L-aspartate (OA)
Study: 12602521
Drug: Intravenous L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-ornithine-L-aspartate (OA)
Study: 2491458
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omeprazole daily
Study: 590310
Drug: 14C‐aminopyrine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C‐aminopyrine 9 mg/kg (pharmacological dose)
Study: 30842115
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg
Study: 25989213
Drug: Forsus Fatigue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forsus Fatigue Resistant Device (FFRD) and mini-implants (FMI)
Study: 22743148
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m²
Study: 22743148
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m²
Study: 19627577
Drug: Inappropriate medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate medication use (long-acting benzodiazepines)
Study: 19627577
Drug: Inappropriate medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate medication use (other inappropriate psychotropics)
Study: 19627577
Drug: Inappropriate medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate medication use (medications with anticholinergic properties)
Study: 17560254
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral calcitriol and calcium carbonate postoperatively (Group 1)
Study: 9331015
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8‐16 mg once‐daily
Study: 31957152
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2%
Study: 3319731
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% and Placebo
Study: 29800250
Drug: LV rehabilitation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LV rehabilitation (low-vision devices with therapy)
Study: 29800250
Drug: Basic LV
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic LV services (low-vision devices without therapy)
Study: 20332484
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus 5-fluorouracil (5-FU)-based adjuvant chemotherapy
Study: 15806211
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide (BUD) 200 microg twice daily
Study: 15806211
Drug: Oral choline
Normalized name: choline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral choline (tricholine citrate, TRI) 500 mg thrice daily
Study: 7822663
Drug: MK-0591 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 (3 oral doses of 250 mg each at 24, 12, and 1.5 hours before allergen inhalation)
Study: 2793717
Drug: Metabolic alkalosis
Normalized name: ALK-4290
DrugBank: ALK-4290 (DB15269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic alkalosis induced by oral administration of NaHCO3
Study: 31033610
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate patch plus eccentric training
Study: 29060739
Drug: Game-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Game-assisted therapy and conventional therapy
Study: 23271794
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg BID
Study: 23271794
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg BID
Study: 20705951
Drug: LPV/r (400mg/100mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r (400mg/100mg) + BILR 355 (150 mg)
Study: 20705951
Drug: BILR 355/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355/r (150 mg/100mg)
Study: 17958625
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (50 mg/kg per day)
Study: 15636137
Drug: Bacterial polycomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial polycomponent vaccine (VP‐4)
Study: 9479761
Drug: Sequential condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential condition (tone offset coinciding with noise onset)
Study: 4921221
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy in Stage I sarcoidosis
Study: 31951780
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of polygeline-free inactivated TBE vaccine (Encepur Adults, GSK) administered approximately 3 years post-primary vaccination.
Study: 24332196
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ivabradine
Study: 24332196
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ivabradine
Study: 24332196
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ivabradine
Study: 21710403
Drug: No-dose-reduction group
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-dose-reduction group (initial optimal therapeutic doses continued throughout the study)
Study: 21710403
Drug: 4-week group
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week group (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction)
Study: 21710403
Drug: 26-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26-week group (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction)
Study: 19131370
Drug: Cilostazol 100mg
Normalized name: CILOSTAZOL 100MG TAB
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg twice a day
Study: 11280845
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen A
Study: 11280845
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen B
Study: 9263085
Drug: Eltanolone (0.41
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone (0.41 +/- 0.1 mg/kg)
Study: 9263085
Drug: Thiopental (2.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (2.88 +/- 0.62 mg/kg)
Study: 9263085
Drug: Etomidate (0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.26 +/- 0.06 mg/kg)
Study: 2963759
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate plus oral placebo (group A, n = 7)
Study: 2963759
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate plus oral medroxyprogesterone acetate (group B, n = 9)
Study: 26268804
Drug: Mass Drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Drug Administration (MDA) with dihydroartemisinin plus piperaquine (DHAp)
Study: 26268804
Drug: Focal Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal Mass Drug Administration (fMDA) with dihydroartemisinin plus piperaquine (DHAp)
Study: 26268804
Drug: No mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mass treatment (standard of care)
Study: 16787512
Drug: Timcodar dimesylate
Normalized name: Timcodar
DrugBank: Timcodar (DB12761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timcodar dimesylate 12.5 mg/day
Study: 16787512
Drug: Timcodar dimesylate
Normalized name: Timcodar
DrugBank: Timcodar (DB12761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timcodar dimesylate 50 mg/day
Study: 14504873
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg 1 h before operation (group R)
Study: 14504873
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg 1 h before surgery (group N)
Study: 10865480
Drug: Otomize ear
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Otomize ear spray
Study: 9108642
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg b.i.d. sodium valproate (VPA)
Study: 9108642
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg b.i.d. sodium valproate (VPA)
Study: 9108642
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of sodium valproate (VPA)
Study: 8474201
Drug: HA-1A (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (10 mg.kg-1)
Study: 8474201
Drug: Control (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (human IgM antibody 10 mg.kg-1 and human serum albumin)
Study: 8474201
Drug: Control human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control human IgM antibody
Study: 24588407
Drug: Multisystemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy adapted for health care settings (MST‐HC)
Study: 21813900
Drug: Short-acting beta
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta agonists
Study: 21813900
Drug: Long-acting bronchodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting bronchodilators
Study: 14564337
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (15 mg/24 hours)